B. Sikorska and P. P. Liberski, Human prion diseases: from kuru to variant creutzfeldt-jakob disease, Subcell Biochem, vol.65, pp.457-496, 2012.

P. Parchi and D. Saverioni, Molecular pathology, classification, and diagnosis of sporadic human prion disease variants, Folia Neuropathol, vol.50, pp.20-45, 2012.

S. B. Prusiner, Novel proteinaceous infectious particles cause scrapie, Science, vol.216, pp.136-144, 1982.

H. Bueler, A. Aguzzi, A. Sailer, R. A. Greiner, and P. Autenried, Mice devoid of PrP are resistant to scrapie, Cell, vol.73, pp.1339-1347, 1993.

A. Sailer, H. Bueler, M. Fischer, A. Aguzzi, and C. Weissmann, No propagation of prions in mice devoid of PrP, Cell, vol.77, pp.967-968, 1994.

G. Mallucci, A. Dickinson, J. Linehan, P. C. Klohn, and S. Brandner, Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis, Science, vol.302, pp.871-874, 2003.

K. Chang, S. J. Elledge, and G. J. Hannon, Lessons from Nature: microRNAbased shRNA libraries, Nat Methods, vol.3, pp.707-714, 2006.

G. J. Hannon, RNA interference, Nature, vol.418, pp.244-251, 2002.

G. Mallucci and J. Collinge, Rational targeting for prion therapeutics, Nat Rev Neurosci, vol.6, pp.23-34, 2005.

G. R. Mallucci, M. D. White, M. Farmer, A. Dickinson, and H. Khatun, Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice, Neuron, vol.53, pp.325-335, 2007.

M. D. White, M. Farmer, I. Mirabile, S. Brandner, and J. Collinge, Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease, Proc Natl Acad Sci U S A, vol.105, pp.10238-10243, 2008.

M. D. White and G. R. Mallucci, RNAi for the treatment of prion disease: a window for intervention in neurodegeneration?, CNS Neurol Disord Drug Targets, vol.8, pp.342-352, 2009.

M. D. White and G. R. Mallucci, Therapy for prion diseases: Insights from the use of RNA interference, Prion, vol.3, pp.121-128, 2009.

M. A. Pouladi, E. Brillaud, Y. Xie, P. Conforti, and R. K. Graham, NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease, Neurobiol Dis, vol.48, pp.282-289, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01545519

P. Parini, L. Johansson, A. Broijersen, B. Angelin, and M. Rudling, Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system, Eur J Clin Invest, vol.36, pp.98-104, 2006.

M. Wroblewska, The origin and metabolism of a nascent pre-beta high density lipoprotein involved in cellular cholesterol efflux, Acta Biochim Pol, vol.58, pp.275-285, 2011.

V. I. Zannis, A. Chroni, and M. Krieger, Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL, J Mol Med (Berl), vol.84, pp.276-294, 2006.

P. Brown, An historical perspective on efforts to treat transmissible spongiform encephalopathy, CNS Neurol Disord Drug Targets, vol.8, pp.316-322, 2009.

K. Toupet, V. Compan, C. Crozet, C. Mourton-gilles, and N. Mestre-frances, Effective gene therapy in a mouse model of prion diseases, PLoS ONE, vol.3, p.2773, 2008.
URL : https://hal.archives-ouvertes.fr/hal-01667611

A. Relano-gines, A. Gabelle, S. Lehmann, O. Milhavet, and C. Crozet, Gene and cell therapy for prion diseases, Infect Disord Drug Targets, vol.9, pp.58-68, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00367789

A. Relano-gines, S. Lehmann, A. Bencsik, M. E. Herva, and J. M. Torres, Stem cell therapy extends incubation and survival time in prion-infected mice in a time window-dependant manner, J Infect Dis, pp.1038-1045, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00635996

B. Pulford, N. Reim, A. Bell, J. Veatch, and G. Forster, Liposome-siRNApeptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures, PLoS ONE, vol.5, p.11085, 2010.